A multi-Center, Open-Label Phase II Study of Single-Agent GX15-070MS [obatoclax] Administered as a 24-Hour Infusion Every 2 Weeks to Patients With Relapsed or Refractory Hodgkin's Lymphoma

Trial Profile

A multi-Center, Open-Label Phase II Study of Single-Agent GX15-070MS [obatoclax] Administered as a 24-Hour Infusion Every 2 Weeks to Patients With Relapsed or Refractory Hodgkin's Lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2012

At a glance

  • Drugs Obatoclax (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Gemin X Biotechnologies
  • Most Recent Events

    • 01 Mar 2012 Results have been published in a letter in the journal Blood.
    • 11 Sep 2010 Actual end date (1 Nov 2008) added as reported by ClinicalTrials.gov.
    • 10 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top